Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
Research grant to understand and treat long-term side effects of cancer therapy through mechanistic and clinical studies supporting therapeutic interventions.
Funder: National Institutes of Health
Due Dates: June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | February 5, 2026 (New) | March 5, 2026 (Renewal/Resubmission/Revision) | June 5, 2026 (New) | July 5, 2026 (Renewal/Resubmission/Revision) | October 5, 2026 (New) | November 5, 2026 (Renewal/Resubmission/Revision) | February 5, 2027 (New) | March 5, 2027 (Renewal/Resubmission/Revision) | June 5, 2027 (New) | July 5, 2027 (Renewal/Resubmission/Revision) | October 5, 2027 (New) | November 5, 2027 (Renewal/Resubmission/Revision)
Funding Amounts: No budget cap; budgets must reflect actual needs. Maximum project period: 5 years.
Summary: Supports research to understand, characterize, and mitigate long-term adverse effects of cancer therapies through mechanistic, translational, and clinical studies.
Key Information: Both U.S. and non-U.S. organizations are eligible; clinical trials are optional; applications requesting ≥$500,000 direct costs in any year require prior contact with NIH.
Description
This NIH opportunity, administered by the National Cancer Institute (NCI), funds research projects that address adverse sequelae of cancer therapies—side effects that persist, become chronic comorbidities, or develop as delayed posttreatment effects. The program supports basic, translational, and clinical research to:
- Identify mechanisms underlying therapy-induced adverse sequelae
- Clinically characterize these sequelae
- Translate mechanistic understanding into interventions to prevent or minimize long-term effects
Projects should emphasize mechanistic studies with translational endpoints and longitudinal clinical phenotyping, aiming to identify and validate clinical endpoints (such as biomarkers, imaging, or patient-reported outcomes) for future clinical trials of interventions.
Research may focus on adult or pediatric populations and should address chronic, progressive, or late effects of cancer therapies (including chemotherapy, immunotherapy, targeted/hormonal therapies, and radiation). Collaborative projects that bridge basic and clinical research are encouraged, as are studies involving underserved populations and emerging cancer treatments.
Non-responsive applications include those focused solely on acute, reversible, or non-progressive adverse effects, resistance to cancer treatment, non-FDA approved agents in preclinical models, or adverse events in non-cancer conditions.
